<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04223752</url>
  </required_header>
  <id_info>
    <org_study_id>7625A-036</org_study_id>
    <secondary_id>MK-7625A-036</secondary_id>
    <secondary_id>2018-004704-19</secondary_id>
    <nct_id>NCT04223752</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)</brief_title>
  <official_title>A Phase 1, Open-label, Non-comparative, Multicenter Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ceftolozane/Tazobactam (MK-7625A) in Pediatric Participants With Nosocomial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label, non-comparative, multicenter clinical study to evaluate the
      safety, tolerability, and pharmacokinetics of ceftolozane/tazobactam (MK-7625A) in pediatric
      participants with nosocomial pneumonia (NP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Anticipated">February 22, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with any adverse events (AEs)</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any serious AEs (SAEs)</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>An SAE is any untoward medical consequence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or any other important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any drug-related AEs</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>A drug-related AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, and considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with any drug-related SAEs</measure>
    <time_frame>Up to 31 days</time_frame>
    <description>A drug-related SAE is any untoward medical consequence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or any other important medical event, that is considered related to the study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with AEs leading to discontinuation of study intervention</measure>
    <time_frame>Up to 14 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma concentrations of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of an 8-hour dosing interval (AUC0-8) of plasma ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma AUC0-8 of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of an 8-hour dosing interval (AUC0-8) of plasma tazobactam</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma AUC0-8 of tazobactam will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration during a dosage interval (Cmax) of plasma ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma Cmax of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration during a dosage interval (Cmax) of plasma tazobactam</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma Cmax of tazobactam will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2) of plasma ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma t1/2 of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (t1/2) of plasma tazobactam</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma t1/2 of tazobactam will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of plasma ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma Vd of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of plasma tazobactam</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma Vd of tazobactam will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of plasma ceftolozane</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma CL of ceftolozane will be determined in each group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of plasma tazobactam</measure>
    <time_frame>Day 3: 1, between 4-5, and between 7-8 hours after start of infusion</time_frame>
    <description>The plasma CL of tazobactam will be determined in each group.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Nosocomial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Group 1: Ceftolozane/Tazobactam 12 to &lt;18 Years of Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 12 to &lt;18 years of age with nosocomial pneumonia receive intravenous (IV) ceftolozane/tazobactam every 8 hours for 8-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Ceftolozane/Tazobactam 7 to &lt;12 Years of Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 7 to &lt;12 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Ceftolozane/Tazobactam 2 to &lt;7 Years of Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 to &lt;7 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Ceftolozane/Tazobactam 3 Months to &lt;2 Years of Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 3 months to &lt;2 years of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Ceftolozane/Tazobactam Birth to &lt;3 Months of Age</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from birth to &lt;3 months of age with nosocomial pneumonia receive IV ceftolozane/tazobactam every 8 hours for 8-14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/Tazobactam</intervention_name>
    <description>Participants 12 to &lt;18 years of age: IV ceftolozane 2 g with tazobactam 1 g infused over a 60-minute period.
Participants &lt;12 years of age: IV ceftolozane 40 mg/kg with tazobactam 20 mg/kg infused over a 60-minute period (not to exceed a dose of ceftolozane 2g and tazobactam 1 g).</description>
    <arm_group_label>Group 1: Ceftolozane/Tazobactam 12 to &lt;18 Years of Age</arm_group_label>
    <arm_group_label>Group 2: Ceftolozane/Tazobactam 7 to &lt;12 Years of Age</arm_group_label>
    <arm_group_label>Group 3: Ceftolozane/Tazobactam 2 to &lt;7 Years of Age</arm_group_label>
    <arm_group_label>Group 4: Ceftolozane/Tazobactam 3 Months to &lt;2 Years of Age</arm_group_label>
    <arm_group_label>Group 5: Ceftolozane/Tazobactam Birth to &lt;3 Months of Age</arm_group_label>
    <other_name>MK-7625A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is hospitalized and anticipated to receive a minimum of 8 days of concomitant
             standard-of-care [SOC] antibiotic therapy for proven or suspected NP.

          -  If male, is abstinent from heterosexual intercourse, or agrees to use contraception
             during the intervention period and for ≥30 days after the last dose of study
             intervention.

          -  If female, is not pregnant or breastfeeding, or is not a woman of childbearing
             potential (WOCBP), or is a WOCBP using acceptable contraception, is a WOCBP with
             negative urine or serum pregnancy test within 48 hours of the first dose of study
             intervention, or is abstinent from heterosexual intercourse.

        Exclusion Criteria:

          -  Has a documented history of any moderate or severe hypersensitivity (or allergic)
             reaction to any β-lactam antibacterial.

          -  Participants 3 months to &lt;18 years of age: has moderate to severe impairment of renal
             function, defined as an estimated creatinine clearance (CrCL) &lt;50 mL/min/1.73 m2 based
             on the revised Schwartz equation or requirement for peritoneal dialysis, hemodialysis,
             or hemofiltration.

          -  Participants &lt;3 months of age: has CrCL &lt;20 mL/min/1.73 m2 based on the revised
             Schwartz equation or requirement for peritoneal dialysis, hemodialysis, or
             hemofiltration.

          -  Is receiving or is anticipated to receive piperacillin/tazobactam while receiving
             ceftolozane/tazobactam or has received piperacillin/tazobactam within 24 hours prior
             to the first dose of ceftolozane/tazobactam.

          -  Has participated in any clinical study of a therapeutic investigational product within
             30 days prior to the first dose of ceftolozane/tazobactam.

          -  Has previous participation in any study of ceftolozane or ceftolozane/tazobactam.

          -  Has any condition or circumstance that, in the opinion of the investigator, would
             compromise the safety of the participant or the quality of study data.

          -  Has any rapidly progressing disease or immediately life-threatening illness including
             acute hepatic failure or septic shock.

          -  Has active immunosuppression.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montefiore Medical Center [Bronx, NY] ( Site 1313)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>718-741-2470</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanford Children's Hospital ( Site 1301)</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>605-312-1000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Virginia University ( Site 1310)</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>304-293-1015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Tallinna Lastehaigla/Tallinn Children's Hospital ( Site 0201)</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+37255573326</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SA Tartu Ulikooli Kliinikum Lastekliinik ( Site 0200)</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+3727319550</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Deu ( Site 1100)</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+34932532100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 1205)</name>
      <address>
        <city>Dnipro</city>
        <state>Dnipropetrovska Oblast</state>
        <zip>49100</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380509142649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kharkiv City Children Hospital 16 ( Site 1200)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61075</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+380953831851</phone>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 10, 2020</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

